| Ticker Details |
Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a US-based biopharmaceutical company. The firm is engaged primarily in developing medicines for patients suffering with rare neurological disorders.
|
| IPO Date: |
May 10, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$461M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.13 | 3.40%
|
| Avg Daily Range (30 D): |
$0.07 | 2.69%
|
| Avg Daily Range (90 D): |
$0.08 | 3.63%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.66M |
| Avg Daily Volume (30 D): |
2.09M |
| Avg Daily Volume (90 D): |
2.49M |
| Trade Size |
| Avg Trade Size (Sh.): |
225 |
| Avg Trade Size (Sh.) (30 D): |
158 |
| Avg Trade Size (Sh.) (90 D): |
208 |
| Institutional Trades |
| Total Institutional Trades: |
134 |
| Avg Institutional Trade: |
$2M |
| Avg Institutional Trade (30 D): |
$.7M |
| Avg Institutional Trade (90 D): |
$1.31M |
| Avg Institutional Trade Volume: |
.56M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.22M |
| Avg Closing Trade (30 D): |
$.55M |
| Avg Closing Trade (90 D): |
$1.77M |
| Avg Closing Volume: |
805.35K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
|
|
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$M
|
$.72M
|
$7.25M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-16.99M
|
$9.66M
|
$-17.41M
|
|
Operating Income / Loss
|
$-17.85M
|
$-12.29M
|
$-42.44M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$81.03M
|
$-7.29M
|
$-12.98M
|
|
PE Ratio
|
|
|
|
|
|
|